Ministry of Health registered Levilimab drug for treatment of severe form COVID-19 – Society


MOSCOW, June 6. / TASS /. According to the accelerated procedure, the Ministry of Health issued a registration certificate for the drug “Levilimab” (trade name “Ilsira”) for the treatment of patients with a disease caused by a new coronavirus infection, the press service of the ministry said on Saturday.

“The drug is indicated for patients with a severe course of the disease, when the so-called cytokine storm develops – an excessive inflammatory reaction of the body to the introduction of the virus, which leads to damage to tissues and organs, in particular, lung tissue, to a severe course of infection with a possible fatal outcome. Prevention of the development of cytokine storms are critical in the treatment of COVID-19, “the report said.

The ministry noted that Levilimab was registered under the accelerated procedure provided for by a government decree regulating the specifics of the circulation of drugs in the face of the threat of emergencies and liquidation.

Initially, Levilimab was intended to treat rheumatoid arthritis.


Please enter your comment!
Please enter your name here